Anxiety therapy in the neoplastic patient

Area of Science:

• Oncology
• Psychiatry
• Clinical Pharmacology

Background:

• Anxiety and emotional distress are common in neoplastic patients.
• Effective management of these symptoms is crucial for improving quality of life.

Purpose of the Study:

• To evaluate the efficacy and safety of lorazepam in managing anxiety and related symptoms in cancer patients.
• To determine optimal dosing and treatment duration for lorazepam in this population.

Main Methods:

• A clinical study involving 73 cancer patients with anxiety and emotional disturbances.
• Individualized daily doses of lorazepam (1.5 mg to 3 mg) administered for 15 to 60 days.
• Assessment of symptom response including anxiety, tension, erethism, and insomnia.

Main Results:

• Over 95% of patients experienced some relief from their symptoms.
• Complete symptom resolution occurred in 40% of patients within 15 days.
• Minimal and transient side effects were reported, with most resolving quickly.

Conclusions:

• Lorazepam is a well-tolerated and effective treatment for anxiety and associated symptoms in cancer patients.
• The medication demonstrated significant improvements in emotional well-being and sleep quality.
• Further research could explore long-term efficacy and specific symptom profiles.